In vitro studies have demonstrated that canagliflozin inhibits pancreatic cancer growth by down-regulating GLUT-1 and LDHA and inhibiting glycolysis through the PI3K/AKT/mTOR/HIF-1α signaling pathway at both the mRNA and protein levels, and the combination of this treatment with gemcitabine has shown improved therapeutic efficacy in pancreatic cancer (39). This evidence concerns the gene HIF1A and pancreatic neoplasm.